Journal of Gastrointestinal & Digestive System
Open Access

Review Article

Acute Hepatitis C Virus Infection and Directly Acting Anti-Hepatitis C Virus Drugs

¹Department of Hepatology, National Liver Institute, Menoufia University, Egypt

²Department of Community Medicine, National Liver Institute, Menoufia University, Egypt

³Department of Internal Medicine, Ain Shams University, Egypt

*Corresponding Author:

Omkolsoum M Alhaddad
Department of Hepatology, National Liver Institute
Menoufia University, Egypt
Tel: 002 01001779069
E-mail: dromkolsoum@yahoo.com

Received date: January 23, 2017; Accepted date: March 29, 2017; Published date: April 5, 2017

Citation: Alhaddad OM, Elsabaawy MM, Elshaarawy O, Elsabaawy DM, Mansour T (2017) Acute Hepatitis C Virus Infection and Directly Acting Anti-Hepatitis C Virus Drugs. J Gastrointest Dig Syst 7:496. doi: 10.4172/2161-069X.1000496

Copyright: © 2017 Alhaddad OM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The best of care of Acute hepatitis C (AHC) infections in the evolving era of all oral directly acting antiviral drugs (DDAs) needs revision. The inevitable chronic liver disease in 80% of AHC infections justifies the advent of DDAs that expectedly will guarantee high cure rates. Unlike interferons, the short and ultra-short all oral DDAs regimens had revolutionized treatment strategies with better adherence and fewer complications. However, the costly price of DAAs added to the average expertise is still contrarily active. Up-to-date, studies concerning DAAs treatment for AHC mono-infection are sparse; indeed this represents an unmet need in modern AHC management.

Keywords